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GSK-3 INHIBITORS IN GLIOBLASTOMA THERAPY:  
MECHANISMS OF ACTION 
MEGHAN VICTORIA HANDLEY 
 
ABSTRACT 
 Glioblastoma multiforme (GBM) is the most malignant form of brain cancer. 
Therapies targeting glioblastoma have not consistently been able to give those diagnosed 
the best prognosis. Treatments that directly infiltrate into the tumor are highly sought 
after. Indirubins have been used to treat various types of cancers and are a promising 
avenue for future glioma research. In the current study, we further researched several key 
GSK-3 inhibitors, BIO (an indirubin) and CHIR99021, in addition to LiCl, to see their 
effects on the translocation of β-catenin to the nucleus, and the invasion and migration of 
cells in both a sphere assay and an aortic ring assay.  
Here we studied anti-invasive therapies that may have a future role in GBM 
treatment. It is thought that combining conventional treatments with anti-invasive 
therapies will create cytotoxicity in and reduce migration of the tumor. Three types of 
cells were used throughout the experiments: HBMEC, HUVEC, and U251 glioma cells. 
We reported that GSK-3 inhibitors might have a valuable role in the treatment of GBM. 
The selected inhibitors (BIO, CHIR99021, and LiCl) all were shown to lessen cell 
migration and invasion in vitro in a range of assays and in all cell lines tested. All 
inhibitors tested cause a dose-dependent, reversible inhibition of glioma cell invasion in 
spheroid assays. BIO was shown to cause a rapid upregulation of total and nuclear β-
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catenin. BIO, at higher concentrations, also created a toxic environment for cells, 
sometimes killing them. This shows that a more in-depth experiment involving different 
BIO concentrations is needed to test the optimal concentration for treatment.  
Each of the experimented GSK-3 inhibitors also showed a change in the junctions 
between cells. NaCl as a control showed normal, spikey, junctions, while CHIR99021 
and BIO caused the junctions to become more smooth. This suggests that GSK-3 
inhibition has a role in either maintaining the ECM and/or in communication between 
cells. Also in this assay, there was a heterogeneity between cells treated with the same 
inhibitor and in the same dish, indicating that not all cells respond to each drug the same 
way. The reasons for this are not known and further investigation is required. A new 
construct was also made to report β-catenin transcriptional coactivation using luciferase 
expression as the reporter in response to these selected GSK-3 inhibitors.With the 
combined results of these experiments, we concluded that GSK-3 inhibitors may be a 
promising approach to the treatment of GBM. Further investigation is required before any 
treatments can be administered to those diagnosed.  
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INTRODUCTION 
 
1. GLIOBLASTOMA: THE MOST AGGRESSIVE OF PRIMARY BRAIN 
TUMORS 
Glioblastoma Multiforme (GBM, World Health Organization Grade IV) is a 
neoplasm of the central nervous system (CNS) and is the most malignant form of brain 
cancer. GBM is a primary malignant brain tumor accounting for 80% of all high-grade 
primary CNS cancers, 12-16% of all intracranial neoplasms, and comprising more than 
half of all malignant gliomas (Ray, 2010). GBM is diagnosed in approximately 10,000 
individuals in the United States each year. It has a higher incidence in males and in the 
Caucasian population, and typically affects those aged between 65 and 75, with the 
median age of diagnosis at 64 years. However, GBM is seen in all age groups including 
the pediatric population, although less frequently (Louis et al., 2007; Ray, 2010; 
Schwartzbaum, Fisher, Aldape, & Wrensch, 2006). After diagnosis, patients suffering 
with GBM typically have a median survival of 12 to 14 months with the current standard 
of care consisting of maximal surgical resection followed by concomitant radiation and 
temozolomide treatment (Stupp et al 2005). If diagnosed at an age younger than 44 years, 
however, patients typically have almost a 30% two-year survival rate (Ray, 2010). GBM 
is characterized by the presence of mitotic cells, necrosis and/or angiogenesis and by 
biological hallmark features: “uncontrolled cellular proliferation, diffuse infiltration, 
propensity for necrosis, robust angiogenesis, intense resistance to apoptosis, and rampant 
genomic instability” (Furnari et al., 2007). 
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1.1. Tumor Grading And Pathology 
Although GBM is considered a malignant astrocytoma, it’s precise histogenesis 
remains unclear (Huse & Holland, 2010). Astrocytomas can be diffuse or localized and 
are graded by the World Health Organization (WHO) according to their histopathological 
features of the presence of mitotic cells, along with necrosis and/or angiogenesis. 
Malignant astrocytoma (grade III) has mitoses but necrotic regions and high levels of 
angiogenesis are not seen. Grade II astrocytoma is less aggressive with rare mitotic cells.  
The survival of patients with lower grade astrocytomas is correspondingly longer than 
patients with GBM, and can be over ten years. However, progression of these tumors is 
inevitable, and patients eventually succumb to GBM. This progressive GBM is called 
secondary GBM and accounts for approximately 5% of all cases. The remainder, which 
present as GBM at diagnosis, are known as primary GBM (Louis et al., 2007). Figure 1 
(Preusser, et al., 2011) shows the relative frequencies of the different types of glioma.  
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The majority of GBM tumors are supratentorial (cerebral). A major problem in 
these tumors is that the tumor is not well delineated from the adjacent brain tissue. This is 
because the tumor cells infiltrate into the nearby brain parenchyma. This prevents 
complete surgical resection, and leads to inevitable recurrence.  
The term “multiforme” is used to describe the various appearances on cross 
section: the tumor appears grayish white, the necrotic regions appear yellowish, and often 
there is a red-brown discoloration from a previous hemorrhage. Microscopically, the 
individual cells of GBM have a hyperchromatic nucleus and are of various size and 
shapes. The periphery of the tumor contains infiltrating tumor cells that are able to 
colonize healthy adjacent brain tissue. These infiltrating cells make complete surgical 
resection impossible because of the lack of delineation between the tumor and the normal 
Figure 1. Relative Frequencies of Gliomas. WHO grades are given in 
parentheses. Grades III and IV represent high-grade gliomas (that have a 
worse prognosis), while grades II and I represent lower grade gliomas 
(better prognosis). Figure taken from Preusser et al., 2011. 
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tissue (Ray, 2010). After surgical resection, approximately 90% of patients with GBM 
develop a recurrent tumor adjacent to the original. Satellite lesions have also been shown 
to occur nearby the location of the resected tumor (Lefranc, 2005). Figure 2 (Preusser et 
al., 2011) shows the neuropathology of GBM using slides that demonstrate it’s 
microscopic features. 
 
  
Figure 2. Neuropathology of Glioblastoma. (A) X marks cellular glial tumor tissue 
with central necrosis, arrows mark nuclear pseudopalisading and microvascular 
proliferates (H&E staining). (B) Immunostaining for glial fibrillary acidic protein 
(GFAP), tumor cells appear brown. (C) Immunostaining for CD34 showing 
glomeruloid microvascular proliferates. (D) Immunostaining for Ki67 (cell-cycle 
related antigen), shows tumor cells undergoing mitosis as brown. (Figure taken from 
Preusser, et al., 2011.)	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1.2. Possible Causes  
There are many hypotheses regarding the causes of the different types of glioma.  
A few rare hereditary syndromes, such as neurofibromatosis (neurofibromin mutations), 
tuberous sclerosis, and Li-Fraumeni syndrome (TP53 mutations) are associated with 
GBM accounting for a few percent of total cases. Other potential links include an inverse 
association with allergies (Schwartzbaum et al., 2006). The only known environmental 
cause of GBM is exposure to high doses of ionizing radiation (Preusser et al., 2011) 
There is a higher incidence in the United States and Europe than in Japan, suggesting that 
there may also be underlying environmental factors in the development of glioma tumors 
(Preusser et al., 2011; Schwartzbaum et al., 2006). One of the most controversial areas in 
brain tumor etiology is the effect of cell phone use on tumor incidence.  Although some 
studies have been published supporting the idea that brain tumor incidence in linked to 
the use of cell phones, other larger studies did not establish a link.  However, the National 
Brain Tumor Society recommends that cell phone use is should be limited in children 
(Hardell & Carlberg, 2015).	  	   
 
1.3. Symptoms And Genetics 
Symptoms of GBM include headache, nausea, vomiting, and drowsiness, which 
may be due to increased intracranial pressure as a result of tumor growth. The location of 
the tumor within the brain can also determine additional symptoms, for example, speech 
difficulties, vision changes, hemiparesis, seizures, and changes in personality and 
cognitive behavior (American Brain Tumor Association [ABTA], 2014).  
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Brain tumor cells arise from a transformation process that involves amplification 
or overexpression of oncogenes. This, combined with a loss or under expression of tumor 
suppression genes (p53, retinoblastoma [Rb], p16, p15, and PTEN [phosphatase and 
tensin homolog]), leads to the formation of tumor cells. Examples of oncogenes involved 
include platelet-derived growth factor (PDGF) and it’s receptor, epidermal growth factor 
(EGF) and it’s receptor, CDK4, mdm-2, Ras, Akt, and the mammalian target of 
rapamycin (mTOR). The combination of these two events leads to an imbalance between 
mitosis and apoptosis (Ray, 2010). 
It is known that GBM tumors can be of two major subtypes:  primary GBM (de 
novo) or a secondary GBM, which is a progression from a lower-grade astrocytoma (II or 
III) and only accounts for about 5% of glioblastomas (Yan et al., 2009). Primary GBMs 
are more common in older patients, while secondary GBMs occur more frequently in 
those patients under the age of 45 years (Furnari et al., 2007). While the isocitrate 
dehydrogenase 1 (IDH1) mutation is the defining feature of secondary GBM, TP53 
mutation is theorized to be the initiating event, present in 60% of the tumors that 
eventually evolve to be GBM (Ohgaki & Kleihues, 2007). EGFR gene amplification 
occurs in about 40% of all GBM tumors, and the genes that are usually rearranged 
(Furnari et al., 2007; Louis et al., 2007). Recent investigations have concluded that 
primary and secondary GBMs have very different transcriptional patterns and different 
recurrent DNA copy number aberrations (Furnari et al., 2007). Patients with primary 
GBM have a shorter median survival than those with secondary GBM. With recurrence 
of these gliomas, “less than 50% of patients will survive more than a year” (Ray, 2010). 
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The genetics of GBM are now very well characterized due to the Cancer Genome 
Atlas (TCGA). In this effort, which started in 2006, approximately 500 patient tumor 
samples have been analyzed for chromosomal alterations, mutations, and gene 
expression. This showed that GBM is a heterogeneous disease, with no two tumors 
containing the same mutations. However, the majority of mutations occur in similar 
pathways: tyrosine kinase receptor signaling (often via EGFR amplification or mutation), 
cell cycle deregulation (through mutation of Rb signaling), and cell survival (through 
alterations in p53). Interestingly these efforts and others (Yan et al., 2009) revealed that 
the great majority secondary GBMs have a novel and distinct mutation in the gene 
encoding (IDH1). The most common mutation in IDH1 is R132H, which changes the 
biological activity of IDH1. This leads to the accumulation of 2-hydroxyglutarate within 
tumors, and this is thought to lead to epigenetic changes that drive tumor growth. IDH 
mutation tests could also become of use to distinguish between lower grade astrocytomas 
and those of a higher grade (Yan et al., 2009). A summary of the most common 
mutations is shown in Figure 3 (McLendon, et al., 2008). 
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Comparative genomic hybridization (CGH) profiling of both primary and 
secondary glioblastomas has shown patterns of copy number alterations (CNA; alteration 
in a genome that results in an abnormal variation in the number of copies in a section of 
DNA). Coupling array CGH with additional genomic techniques has allowed more 
investigation into the identities and functions of oncogenes and tumor suppressor genes 
Figure 3. Core Pathway Alterations in GBM. Figure shows examples of 
pathway alterations in GBM. The top panel shows RTK/RAS/PI3K 
signaling, which is altered in 88% of GBM cases. The bottom left shows P53 
signaling, which is altered in 87% of GBM cases, while the bottom right 
shows Rb signaling, which is altered in 78% of cases. The three panels 
together conclude that multiple alterations can happen in each GBM case. 
(Figure taken from McLendon et al., 2008.) 
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that may have roles in the formation and progression of malignant gliomas (Furnari et al., 
2007; Huse & Holland, 2010). These techniques also allow correlation CNA patterns 
with tumor subtypes and clinical outcome (Maher et al., 2006). 
 
1.4. Tumor Diagnosis 
An MRI (magnetic resonance imaging, shown in Figure 4) or CT (computed 
tomography) scan is needed after a thorough neurological exam is performed to obtain an 
accurate determination of the presence of a brain tumor. The initial clinical presentation 
is highly variable and depends on the size and location of the GBM tumor (Preusser et al., 
2011). Sometimes, physicians will also perform a magnetic resonance spectroscopy 
(MRS) scan to measure chemical and mineral levels within the tumor. This scan can give 
clues to whether the tumor is malignant or benign. After these scans, an exact diagnosis 
to the type of tumor requires surgery or a biopsy to obtain a sample of the tumor and a 
thorough examination of the tumor histology using a microscope (Preusser et al., 2011; 
ABTA 2014). 
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Macroscopically, the lesions usually involve more than one lobe of the brain. By 
crossing the corpus callosum, a white matter tract linking the right and left cerebral 
hemispheres, both sides of the brain could be affected by tumor growth, a phenomenon 
called a butterfly GBM.  
 
1.5. Tumor Invasion: A Major Challenge 
Cell migration is an important aspect of the development and evolution of GBM. 
It involves three biologic processes: adhesion, motility, and invasion. Adhesion consists 
Figure 4. MRI of Glioblastoma. (A) Glioblastoma tumor showing irregular 
peripheral ring-like contrast enhancement in the left thalamic region. (B) MRI 
showing heterogeneous hyper-intense mass surrounded by hyper-intense signal 
extending along the adjacent white matter indicating tumor extension and edema. 
(Figure taken from Preusser et al., 2011.)	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of both the adhesion of the cells with the extracellular matrix (ECM) and cell-cell 
adhesion. It has been shown that glioma cells can make and deposit modified ECM 
components (i.e. laminin) that help the cells to move within the brain. Integrins, 
cadherins, and lectins are also important adhesion molecules that help glioma cells 
interact with ECM components (Lefranc, 2005). A loss of cadherin expression is shown 
to promote metastasis in epithelial tumors, but little is known of the effect on GBM cells 
or astrocytes. N-cadherin can bind with β-catenin, which allows the cadherin to bind with 
the actin cytoskeleton. The expression of both N-cadherin and β-catenin may be involved 
in astrocytic tumors (Lefranc, 2005). Another study observed that in malignant gliomas, 
decreased levels of N-cadherin were associated with an increased probability of tumor 
invasion and transport via cerebrospinal fluid (CSF) (Asano et al., 1997). The motility of 
the cells is made possible by the reorganization of the actin cytoskeleton. This 
reorganization can happen because of the polarity of the cells and by actin 
polymerization. Invasion involves the degradation of matrix proteins by proteolytic 
enzymes secreted by the tumor (i.e. matrix metalloproteinases) (Lefranc, 2005).  
 
1.6. Current And Future Prospects For GBM Treatment  
One of the current strategies to treat GBM and other gliomas is to decrease the 
burden of the disease by detecting genetic, environmental, and developmental influences 
to the risk of having a glioma. Treatments used in the past and present include surgical 
removal, radiation, chemotherapy, and gene therapy, however while these have an effect 
on prognosis, they do not show a sufficient cure. Surgery followed by radiation therapy 
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with concomitant temozolomide is now the standard of care for patients diagnosed with 
GBM (Stupp et al 2005). The blood-brain barrier (BBB) and blood-tumor barrier create 
obstacles for drugs to even reach the tumor itself. Although the blood-brain barrier is 
somewhat disrupted in most malignant gliomas, it commonly remains intact in the 
borders where recurrent neoplasm tend to occur (de Vries, Beijnen, Boogerd, & van 
Tellingen, 2006). A few of the ideas currently being investigated to overcome the 
obstacle of the BBB are increasing the dosage of the drug (although this brings in the 
problem of toxicity), conjugating the drug with antibodies, peptides, or viruses, 
packaging drugs in liposomes or micelles, and direct infusion of the drug into the tumor 
via a catheter (Huse & Holland, 2010). 
 
1.6.1. Radiation Therapy 
Radiation therapy has been shown to improve the survival rate of those patients 
suffering from malignant gliomas (Ray, 2010) and is currently an important part of GBM 
treatment (Roger Stupp et al., 2005). A study including newly diagnosed GBM patients 
showed a significant improvement in survival when radiation was combined with 
temozolomide chemotherapy and followed by adjuvant temozolomide. Temozolomide is 
an oral drug that has shown antitumor activity when treating patients with primary 
gliomas. Giving temozolomide on a continuous schedule with radiotherapy allowed 
researchers to administer low, daily doses with an increase in dose intensity without the 
corresponding increase in toxicity. Temozolomide is an alkylating agent that depletes O6-
methylguanine-DNA methyltransferase (MGMT), an enzyme that may be instigated by 
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radiotherapy and is needed to repair damage caused by alkylating agents like 
temozolomide. A low level of MGMT in tumor tissue seems to be associated with a 
longer survival (Hegi et al., 2005). By methylating the MGMT promoter, gene silencing 
is observed and is correlated with a survival benefit not seen with radiotherapy alone. In 
this study, the treatment group had an increased median survival of 14.6 months, an 
increase in survival of 2.5 months when compared with the control group (12.1 months), 
a relative reduction in the risk of death of 37 percent. After two years, the treatment 
group had an increase in survival from 10% (radiotherapy alone) to 26.6% (radiotherapy 
combined with temozolomide) (Roger Stupp et al., 2005).  
 
1.6.2. Viral Therapy 
Several viruses have shown oncolytic properties and will have a lasting effect in 
cancer therapy. Examples of these include, but are not limited to, adenovirus, herpes 
simplex virus-1 (HSV-1), and retrovirus. Oncolytic viruseses can further be used to 
increase the effectiveness of tumor killing by incorporating therapeutic transgenes. 
Selection for tumors can be improved by using glioma-selective promoters to drive the 
expression of viral proteins or transgenes. Current investigations regarding transgenes 
include pro-drug activating (suicide) genes, intracellular signaling molecules, immune 
modulators, and inhibitors of angiogenesis and cell invasion (Lawler, Peruzzi, & 
Chiocca, 2006). Viral infection is designed so viruses will replicate in tumor cells and 
avoid normal cells. They should destroy the tumor by using a variety of mechanisms, for 
example, direct oncolysis, inductions of an anti-tumor immune response, destruction of 
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tumor vasculature, and cancer cell starvation. One of the most broadly studied viruses in 
glioma therapy is recombinant HSV with a deletion in the ICP34.5 gene, which makes 
the virus especially neuro-virulent (Kaufmann & Chiocca, 2014). Studies using oncolytic 
HSV-1 deleted in ICP34.5 showed a toleration, with two out of 21 patients living beyond 
four years after treatment (Rampling et al., 2000).  
 
1.6.3. Signaling Pathways 
Various cell-signaling pathways have been reviewed regarding targets for cancer 
therapy. Oncogenes, tumor suppressors, and apoptotic regulators all contribute to 
gliomagenesis, thereby giving multitudes of potential therapeutic targets (Lawler et al., 
2006). One of these is the phosphoinositide 3 kinase (PI3K)/Akt pathway. The PI3K/Akt 
pathway is commonly upregulated in brain tumors, as a result of the excessive 
stimulation by growth factor receptors and Ras. GBM tumors have a mutation in the 
PTEN tumor suppressor gene in around 40% of primary glioblastomas (Lefranc, 2005; 
Miyashita et al., 2009). Normally, this gene will have an inhibitory effect on the 
activation of protein kinase B signaling, which is dependent on PI3K. PTEN has a role in 
angiogenesis inhibition. A mutation in PTEN will activate the PI3K pathway, a pathway 
correlated with an increased tumor grade, decreased apoptosis, and a worse clinical 
prognosis (Lefranc, 2005). It has also been suggested that GBMs with increased EGFR 
expression are more likely to have a mutation in the PI3K/Akt pathway (Choe et al., 
2003; Narita et al., 2002). The multitude of data regarding this pathway implies that 
irregular PI3K/Akt signaling causes cell proliferation in glioma cells and causes atypical 
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cell migration due to the downregulation of the PTEN tumor suppressor (Lawler et al., 
2006). With this irregularity, chemotherapy and other cytotoxic insults become 
ineffective as the tumor cells gain a resistance. Additionally, inhibition of the PI3K/Akt 
pathway (for example, with BKM120) returns and may strengthen the effectiveness of 
chemotherapy on the glioma cells (Shingu et al., 2003). Another study shows that 
migrating glioma cells have “increased amounts of phosphorylated Akt and its 
downstream substrate glycogen synthase kinase-3 as compared with migration-restricted 
cells” (Joy, 2003). 
Another related pathway with promising potential for cancer therapy is the TOR 
pathway. Rapamycin is an inhibitor of mTOR, while mTOR is a direct target of the 
PI3K/Akt signaling pathway. Rapamycin has a role in the stoppage of cells from the G1 
to S phase of mitosis. It inhibits the phosphorylation of the retinoblastoma protein, which 
commonly occurs in GBM cells as a result of p16 gene (tumor suppressor) inactivation 
(Sekulić et al., 2000). mTOR has also been shown to have a role in cell migration in 
GBM as well as a role in the induction of autophagy. These results show that “inhibition 
of mTOR activity represents a possible means to combat apoptotic-resistant migrating 
GBM cells” (Lefranc, 2005).  
 
1.6.4. Anti-angiogenic Therapy 
Glioblastoma multiforme is highly vascularized, making it a promising candidate 
for anti-angiogenic therapy. Recent experiments have shown that mutations involving the 
PTEN and EGFR genes may act as a switch for the initiation of angiogenesis. Tumor 
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microvessels tend to have poor architecture, meaning that the endothelial cells fail to 
make tight junctions and “have few pericytes and astrocytic foot processes, leaving the 
integrity of the BBB compromised” (Furnari et al., 2007). This can result in increased 
interstitial edema, decreasing local blood flow and leading to tumor hypoxia, 
microhemorrhages and, eventually, areas of necrosis (Furnari et al., 2007). Because 
angiogenesis is required by tumors growing larger than 2-3 millimeters in diameter, anti-
angiogenic therapy has a place in current investigations. Vascular endothelial growth 
factor (VEGF), a highly pro-angiogenic molecule, is the most widely researched and has 
shown disruption of signaling when negative VEGF is virally delivered (Lawler et al., 
2006). Currently, there are three approaches to target VEGF signaling pathways: 
monoclonal antibodies directed against VEGF or its receptor(s), small molecule 
inhibitors of VEGFR-2 tyrosine kinase activity, and soluble decoy receptors created from 
VEGFR1 receptor that selectively inhibit VEGF. Early clinical approaches to anti-
angiogenic therapy have yielded modest results. Radiation and chemotherapy given in 
combination with an anti-angiogenic therapy has shown some benefits, although it is 
unknown if this is due to the effects of the anti-angiogenic therapies (i.e. improved drug 
delivery because of improved vascular flow, improved drug infiltration into the tumor 
because of reduced interstitial pressure, or improved radiation/chemotherapy response 
because of reduced tumor hypoxia) that increase the concentration of the drug within the 
tumor (Lawler et al., 2006). 
Avastin (bevacizumab) is a monoclonal anti-VEGF antibody that has showed 
remarkable effects on imaging and promotion of survival in recurrent GBM. However, 
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two major trials in 2013 failed to show any survival benefit (Chinot et al., 2014). Thus, 
Avastin remains a useful tool, but it is not known how best to use it (Chi, Norden, & 
Wen, 2007). 
 
1.6.5. MicroRNAs 
An additional emerging connection has formed between gliomagenesis and 
microRNA (miR) biology. MiRNAs are single-stranded non-coding RNA molecules of 
around 20-22 nucleotides in length. Some microRNAs have appeared to act as 
oncogenes, called oncomirs. These may function by suppressing tumor suppressor genes, 
allowing the formation of a tumor (Lawler & Chiocca, 2009). It has also been suggested 
that microRNAs allow for continued tumor growth through the maintenance of the stem 
cell-like properties of tumor cells (Godlewski, Newton, Chiocca, & Lawler, 2010). 
MicroRNAs can regulate multiple targets; theorizing that microRNA therapy could offer 
an alternative to highly selective pathway inhibitors (examples mentioned previously) by 
targeting multiple gene networks (Lawler & Chiocca, 2009). For example, “it has 
recently been shown that amplification of miR-26a-2 leads to the overexpression of miR-
25a in 12% of glioblastomas, promoting gliomagenesis through direct repression of 
PTEN, Rb, and MAP3K2” (Huse & Holland, 2010). Many microRNAs have already 
been identified that downregulate the levels of proteins in pathways related to tyrosine 
kinase signaling in GBM, for example, miR-21, miR-27, and miR-124 (Lawler & 
Chiocca, 2009). miR-7 has been shown to suppress EGFR expression and to inhibit the 
Akt pathway. In one study, miR-7 transfection decreased viability and invasiveness of 
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primary GBM cell lines (Kefas et al., 2008). miR-21, miR-124, and miR-128 (which each 
play a role in neural differentiation) have also been shown to be expressed more 
frequently in GBM compared with the normal brain, displaying a possible similarity 
between glioma cells and neural stem cells (Godlewski et al., 2010). In the near future, 
miRNA-based regulation of numerous pathways involved in gliomagenesis should allow 
for additional possible therapies. MicroRNAs could also be used as potential biomarkers 
for diagnosis of GBM and treatment monitoring (Lawler & Chiocca, 2009). 
 
1.6.6. Future Prospects for Treatment and Therapy 
Future glioma research should focus on the role of immune factors in the 
development of glioma tumors. Genetic and environmental factors should be taken 
further into consideration within future studies (Schwartzbaum et al., 2006). New 
treatments should also have more targeted mechanisms of action. Small molecule and 
antibody-based molecular therapeutics have a promising future in the treatment of GBM 
(Ray, 2010). Additionally, particular inhibitors should only be chosen if the target is 
present in the tumor tissue, requiring individualized treatment or molecular profiling 
based on the patient (OʼRourke, 2004). Unfortunately, targeting specific pathways may 
pose challenges of their own, as some are not fully understood and may have more 
functions than currently known. Transgene expression within these pathways may cause 
unforeseen results and effects. Using oncolytic vectors that can propagate throughout the 
tumor also poses a possible treatment (Lawler et al., 2006). 
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2. GSK-3 INHIBITORS AS POTENTIAL ANTI-INVASIVE CANDIDATES FOR 
GLIOBLASTOMA TREATMENT 	  
Glycogen synthase kinase 3 (GSK-3), a serine-threonine protein kinase, has long 
been known as a key enzyme in glycogen metabolism, but is now known to have a role in 
various cellular functions. Examples of these functions include, but are not limited to, 
signaling by insulin, growth factors and nutrients, the fate of cells during embryonic 
development, cell division, apoptosis, and microtubule function (Cohen & Frame, 2001). 
There are two isoforms of GSK-3, GSK-3α and GSK-3β. Having so many functions, 
GSK-3 inhibitors have become a promising idea for the treatment of several types of 
cancers, as well as a therapy for diabetes and Alzheimer’s disease (Cohen & Frame, 
2001). Past research has concluded that GSK-3 has a role in cell proliferation and tumor 
promotion, with an overexpression in colon, pancreatic, liver, and ovarian tumors. GSK-3 
has been shown to confer resistance to chemotherapy, radiation, and other targeted 
therapies, therefore targeting GSK-3 may reduce this resistance and improve patient 
prognosis (McCubrey et al., 2014). 
GSK-3 is one of the enzymes that can phosphorylate glycogen synthase, but, 
unlike other kinases, GSK-3 inhibits the action of glycogen synthase rather than 
activating it. The three-dimensional structure of GSK-3 is very similar to that of mitogen-
activated protein kinase (MAPK) (Cohen & Frame, 2001). GSK-3 can be inhibited in 
response to the phosphorylation of one serine residue in its structure (S9). Kinases that 
are known to phosphorylate GSK-3β include protein kinase A (PKA) and Akt, among 
several growth factors, including EGF and PDGF (McCubrey et al., 2014). 
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GSK-3 has a role in migration-associated pathways, including Wnt (explained 
further below), Notch, growth factor, and G-protein coupled receptor signaling (Williams 
et al., 2011). GSK-3 is regulated by many upstream signals and can function 
independently in multiple pathways, suggesting that while GSK-3 inhibition may have 
effects on tumor invasion, it may also have oncogenic properties (Nowicki et al., 2008). 
GSK-3 may function as a tumor suppressor in some tumor types by suppressing 
the Wnt/β-catenin pathway. Wnts have a specific function in a pathway involved in the 
fate of cells during embryonic development, and their targets include a GSK-3 that can be 
complexed to β-catenin (a proto-oncoprotein). β-catenin is stabilized by GSK-3, giving 
GSK-3β oncogenic properties (McCubrey et al., 2014). β-catenin is targeted for 
ubiquitination and proteosomal degradation after being phosphorylated by GSK-3. This 
complex is disturbed during Wnt signaling, which prevents GSK-3 from phosphorylating 
β-catenin. When β-catenin is not phosphorylated, it is no longer targeted for degradation 
and will increase its transcription, and will have a prominent role in tumor invasion and 
proliferation. This suggests that GSK-3 plays a role in glioma migration through the 
regulation of β-catenin, although other pathways may contribute. Unfortunately, since 
GSK-3 inhibitors mimic the Wnt signaling pathway, they could become oncogenic with 
prolonged use (Cohen & Goedert, 2004). An overview of the Wnt signaling pathway 
involving GSK-3 is shown in Figure 5 (McCubrey et al., 2014).  
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One study (Miyashita et al., 2009) showed that GSK-3β inhibition provides 
several benefits: reduced tumor proliferation and protection of brain tissue from 
degradation. Healthy brain tissue shows less expression of GSK-3β, making the 
neoplastic tissue more susceptible to inhibition. The same study found that GSK-3β 
Figure 5. Wnt/β-catenin as Modulated by GSK-3. If Wnt is present, β-catenin is 
stabilized and can induce gene transcription. Wnt binds its co-receptors Frizzled and 
LRP5/6. Frizzled is shown as a squiggly line (as it is a transmembrane receptor) and 
LRP5/6 are shown as an oval. Yellow ovals represent various molecules that interact 
with the receptors. In the present of Wnt, β-catenin is stabilized and complexes with 
TCF/LEF (yellow diamond). Pink circles represent various proteins that can interact 
with the transcription factor complexes. (Figure taken from McCubrey et al., 2014.) 	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inhibition induced the expression of p53 and p21, two known tumor suppressor genes, in 
two different cell lines harboring wild-type p53. GSK-3β also decreased the levels of Rb 
phosphorylation and activation. Thus, inhibition of GSK-3β decreases proliferation and 
survival and increases apoptosis in GBM cells via an activating Rb-mediated pathway. 
CDK6 seems to have a role in regulation in the proliferation of these cells. Therefore, 
further investigation is necessary to determine the role of GSK-3β in CDK6 activity. As a 
result of this study, it is thought that using GSK-3β inhibitors will increase the 
radiosensitivity of GBM tumors to the combination of temozolomide and chemotherapy 
through decreases in Rb phosphorylation and CDK6 expression (Miyashita et al., 2009).  
Another study showed that GSK-3β phosphorylates PTEN (a tumor suppressor 
gene mentioned in section 1.3), which causes it to be destabilized. Inhibition of GSK-3β 
allowed PTEN to regain stability in GBM cells, and helped to increase p53 activity and 
thereby cell cycle arrest (Miyashita et al., 2009). A third study by Williams et al. (2011) 
involving GSK-3 showed that β-catenin played a role in facilitating the effects of GSK-3 
on glioma cell motility. This study showed that, among other things, β-catenin 
knockdown leads to less cell-cell adhesion and that β-catenin phosphorylation increases 
during a glioma cell migration assay.  
One example of a GSK-3 inhibitor is lithium, which has already been used for 
some time in the treatment of bipolar disorder. Lithium also has effects on metabolism, 
neuronal communication, and cell proliferation and development, all of which are cell-
type- and dose-dependent (Nowicki et al., 2008). A study by Nowicki et al. (2008) 
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showed that lithium chloride (LiCl) caused a near complete blockage of cellular invasion 
and slowed cell proliferation in glioma spheroids.  
Indirubins, another example GSK-3 inhibitors, have been traditionally used by the 
Chinese Academy of Medicine for the treatment of certain types of leukemia (Kim, Shin, 
Kang, & Park, 2011). They have been shown to provoke cell cycle arrest at the G2/M 
phase by inhibiting GSK-3, among other things. Indirubins have a role in anti-angiogenic 
mechanisms that prevent tumor growth and invasion (Kim et al., 2011). Various indirubin 
derivatives have been examined, including 6-bromoindirubin-oxime (BIO), BIA, and 
indirubin 3’-oxime (IO). In one study (Williams et al., 2011), a rapid reduction of the 
phosphorylation of β-catenin was seen after treatment with BIO, but not with lithium 
chloride (LiCl), showing that BIO leads to a stronger GSK-3 inactivation than lithium 
and a decrease in cell migration. The same study concluded that indirubins are more 
effective at blocking migration than other inhibitors examined previously, improving 
survival. These data show that indirubins are viable candidates from which to base further 
anti-angiogenic and anti-invasive therapies for gliomas (Williams et al., 2011). BIO and 
other indirubins are very non-selective and inhibit many kinases, also making them 
valuable contenders for GBM therapy. 
 
2.1. Research Question 
Studies on the effects of these various GSK-3 inhibitors in tumors have shown 
diverse effects (e.g., anti-angiogenesis, promotion of cell death, and inhibition of cell 
motility). In this study, we aimed to further understand these effects by examining the 
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effects of a panel of GSK-3 inhibitors (BIO, CHIR99021, LiCl) on glioma cells and 
endothelial cells in vivo.  As a second part of this study we also developed a glioma cell 
line stably expressing a luciferase gene downstream of the β-catenin promoter.  This 
allowed a direct readout of GSK-3 inhibition in glioma cells, and will be useful for in 
vivo drug delivery studies in the Lawler Laboratory. 
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METHODS 
 
1. BIOLOGICAL EFFECTS OF GSK-3 INHIBITORS 
1.1. Cell Culture 
Human glioblastoma cell lines U251 and G9 (#1062047 prepared on 10/12/06) 
were obtained from American Type Tissue Collection (Rockland, MD) and Ohio State 
University (OSU), respectively. Human tissue was procured using established procedures 
as defined in OSU tissue procurement facility protocols approved by the Institutional 
Research Board. HBMEC and HUVEC cells were obtained from Sciencell (Carlsbad, 
CA). U251 cells were maintained in DMEM supplemented with 10% fetal bovine serum. 
G9 cells were maintained in Neurobasal medium (Life Technologies, Grand Island, NY) 
supplemented with b27, EGF (epidermal growth factor), and FGF (fibroblast growth 
factor) and without Vitamin A. EGF and FGF were given at 10ng/mL and were obtained 
from Peprotech (Rocky Hill, NJ). HBMEC were cultured in Endothelial Cell Medium 
(Sciencell) supplemented with 10% fetal bovine serum and 5mL of endothelial cell 
growth supplement. HUVEC were cultured in Endothelial Cell Medium (Sciencell) 
supplemented with 10% fetal bovine serum and 5mL of endothelial cell growth 
supplement. All cells were kept at 37ºC while in culture. 
 
1.2. Immunohistochemistry 
HUVEC, HBMEC, and U251 were all cultured on 8-chamber Lab-Tek glass 
slides. The cells were treated with selected GSK-3 inhibitors (LiCl, 20mM; BIO, 2uM; 
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CHIR99021, 2uM) and controls (NaCl, 20mM; and DMSO) and allowed to incubate 
overnight. Cells were washed once with cold DPBS (Dubecco’s Phosphate Buffered 
Saline, Life Technologies). Cells were then fixed in 4% paraformaldehyde solution and 
washed with DPBS supplemented with 0.1% Triton X-100 (Sigma-Aldrich) solution. 
Blocking was carried out using with normal donkey serum (non-immunized, from 
Jackson ImmunoResearch, West Grove, PA). Slides were then incubated overnight in 4ºC 
with the primary antibody, mouse anti-beta-catenin (1:500) (from Cell Signaling). Next, 
the cells were washed several times with the DPBS-Triton X-100 solution. Thereafter, a 
fluorescently labeled secondary antibody (488 nm Alexa Fluor anti-mouse, 1:1000; from 
Jackson ImmunoResearch) and blue channel DNA stain DAPI (Life Technologies) were 
applied and the cells were allowed to incubate for six hours. The cells were washed again 
several times with the DPBS-Triton X-100 solution. A coverslip was applied and images 
were recorded with a ZEISS LSM710 confocal microscope with appropriate filter 
settings. 
 
1.3. Adherens Junctions in Live Cells 
G9 cells were transfected with pEGFP-C1/beta-catenin using Lipofectamine 2000 
(Life Technologies) using established transfection procedures. Individual clones were 
selected for under Geneticin conditions (Life Technologies). These cells were then 
seeded (20,000 cells per chamber) on a Nunc Lab-Tek chambered coverglass (Thermo 
Fisher Scientific Inc.) and imaged using a Nikon TE2000 with an on-stage incubator with 
a lens magnification of 60X. The cells were then exposed to selected GSK-3 inhibitors 
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(LiCl, 20mM;BIO, 2uM; CHIR99021, 2uM) and the control (NaCl, 20mM). Images were 
collected in a time-lapse fashion using appropriate settings. 
 
1.4. Electric Cell-Substrate Impedance Sensing (ECIS) 
HBMEC cells were cultured as described above. 25,000 cells were added to each 
chamber containing a single circular 250µm diameter active electrode (ECIS Cultureware 
Disposable Electrode Arrays, Applied Biophysics). The cells were grown to confluency 
(about four days). Drugs were added to the chambers immediately before running the 
ECIS machine (ECIS Zθ, Applied Biophysics, Inc., Troy, NY). Resistance was recorded 
for 24 hours for adherens junction data and for 20 days for tight junction data. The goal 
was to obtain a phase of plateau of resistance, which would indicate the maturation of 
tight junctions. 	  
 
1.5. Rat Aortic Ring Assay 
 A Wistar rat was obtained from Charles River Laboratories International, Inc. The 
rat was killed using a ketamine overdose followed by a cervical dislocation as described 
in the protocol. The rat’s abdominal aorta was extracted and was stripped from the 
connective tissue. Aortic rings were cut in 0.5mm portions and were embedded in a 
collagen I (neutralized and supplemented with 5% fetal bovine serum) matrigel mixture 
(90:10). The embedded rings were overlaid with full-grown medium supplemented with 
rat-FGF (10ng/mL). NaCl, LiCl, DMSO, CHIR99021, and BIO dilutions adjusted for 
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final concentration were applied to each well containing the aortic rings. The rings plus 
drugs were allowed to migrate for six days. Cells were stained by adding calcein AM 
(0.5mg/mL, Life Technologies). Images were collected in the green channel of the Nikon 
Ti fluorescent microscope. A 3D Z-stack was collected and collapsed with an increased 
depth of field.  
 
1.6. HBMEC Sphere Assay 
HBMEC were obtained as stated previously. Cells were put in a 96-well round 
bottom, low attachment plate (Corning, Inc.). They were incubated overnight to reach the 
desired cell aggregation. The medium was replaced with a neutralized collagen I solution. 
After polymerization, the gel was overlaid with medium containing the appropriate drugs 
dilutions (NaCl, 20mM; LiCl, 20mM; DMSO, 0.1%; CHIR99021, 10uM; BIO, 5uM). 
After 96 hours treatment, images were taken on the Nikon Ti microscope. Outgrowth 
areas and perimeters were measured. 
 
2. CLONING AND TCF-LEF LUCIFERASE REPORTER ASSAY 
The M50 and M51 (M50 - pTA/Super8XTOPflash – b-catenin binding; M51 - 
pTA/Super8XFOPflash – b-catenin NoBinding) plasmids were provided by Dr. Randall 
Moon, University of Washington, Seattle, WA. The plasmid DNA was then isolated from 
DH5α bacterial cultures. The pTA plasmid provided a sequence of 8xTCF-LEF-TA 
(TCF-LEF – sequence allowing binding of TCF-LEF transcription factor, TA – minimal 
eukaryotic promoter) sequence that served as the insert to be cloned into pGL4.14 
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plasmid (Promega). 
The plasmid DNA was isolated from 5mL cultures using the PureLink Quick 
Plasmid Miniprep Kit (Invitrogen, Carlsbad, CA). In more detail: Bacterial cultures were 
spun for 10 minutes at 6000 rpm to collect bacterial cells; Pellets were resuspended in 
resuspension buffer (50mM Tris-HCL, pH 8.0, 10mM EDTA) before being applied to the 
column; Cells were lysed using an alkaline/SDS procedure (200mM NaOH, 1% w/v 
SDS) and the lysate was applied to a silica membrane spin column that selectively binds 
plasmid DNA. Contaminants were removed using Wash Buffer and the plasmid DNA 
was eluted in preheated TE Buffer (10mM Tris-HCL, pH 8.0, 0.1mM EDTA). A 
microcentrifuge at room temperature was used for all procedural steps and was spun at 
>12,000 x g.   
 The purified pTA plasmids were cut using restriction enzymes HindIII-HF (sticky 
ends, high-fidelity) and SacI (sticky ends) (both New England BioLabs Inc.). pGL4.14 
(obtained from Promega) served as the plasmid vector for new construct. The pGL4.14 
plasmid was also cut with HindIII-HF and SacI restriction enzymes. 
The digestion mixture consisted of 1 µg of the DNA plasmid obtained from the 
PureLink Quick Plasmid Miniprep Kit (Invitrogen), 1.0 uL of NEBuffer 2.1 (New 
England BioLabs Inc.), 0.5 µL of both HindIII and SacI, and 7 µL of deionized water. 
They were digested in a 37 degrees Celsius water bath for a period of one hour. 
Nucleic acids digested were mixed with loading buffer (20 % Ficoll 400, 0.1 M 
Na2EDTA, pH 8, 1.0% sodium dodecyl sulfate, 0.25 % bromphenol blue, 0.25 % xylene 
cyanol) and run on a 1% agarose/ethyl bromide/1xTAE gel. 1ug Ready load 1kb DNA 
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ladder (Invitrogen) was run as a standard. The gel was run at 5 volts per cm of tank 
length (150V). The gel was visualized using the BioRad ChemiDoc XRS. The desired 
vector and desired insert was cut out of the gel and purified using the protocols 
established in the PureLink Quick Gel Extraction Kit (Invitrogen).  
The purified insert vector were ligated using protocols established in the Quick 
Ligation Kit (New England BioLabs Inc.). Bacteria (DH5-alpha competent E. Coli) were 
transformed with 1.0 uL of the ligation mixture and plated overnight. Colonies were 
expanded to 5ml liquid culture and DNA was isolated as established in the PureLink 
Quick Plasmid Miniprep Kit (Invitrogen). This DNA was cut with the same restriction 
enzymes (HindIII and SacI as mentioned previously) to determine if our desired DNA 
fragment had been inserted. The cloning procedure yielded two new DNA constructs 
named: pGL4.14/Super8XTOPflash or pGL4.14/8xTCF-LEF-TA-b-catenin-Binding and 
pGL4.14/Super8XFOPflash or pGL4.14/8xTCF-LEF-TA-b-catenin-NO-Binding. 
The amount of plasmids DNA was scaled up as established in the PureLink 
HiPure Plasmid Filter Maxiprep Kit (Life Technologies). Using Lipofectamine 3000 
reagent, the plasmids were introduced into U251 glioma cells. The mixture of stable 
clones was selected using Hygromycin B (150 ug/mL, Life Technologies). The 
U251/pGL4.14/8xTCF-LEF-TA-b-catenin-Binding cells were plated in 96-well white 
wall plates, 10,000cells/well, in 84 wells. 
 The chosen GSK-3 inhibitors, BIO and CHIR99021 were used in seven dilutions 
(serial two times dilution from 10uM). Each dilution was done in triplicate, with a 6-hour 
incubation period to allow TCF-LEF-TA-dependent accumulation of Luciferase. The 
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U251/pGL4.14/8xTCF-LEF-TA-b-catenin-No-Binding cells were used as a negative 
control, reflecting basal (very low) level of luciferase translation from the TA minimal 
eukaryotic promoter. Medium was removed, and cells were lysed using the Steady-Glo 
Luciferase Assay System (Promega), which also provides a luciferin substrate. Light 
output from luciferase directly reflects promoter activity; signal was determined by 
measuring luciferase levels in a Fluostar Optima plate reader (BMG Labtech, Durham, 
NC).  
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RESULTS 
As described in the introduction, small molecule GSK-3 inhibitors have been 
previously shown to have potentially beneficial effects in vitro and in animal models of 
GBM.  In order to further understand the potential roles of GSK-3 inhibition in GBM we 
performed two sets of experiments. First we studied cultured GBM cells and endothelial 
cells in order to gain insight into the effects of these inhibitors on the behavior of these 
cells, with particular emphasis on the GSK-3 substrate β-catenin. Second, we created a 
GBM cell line carrying a genetic reporter to enable the visualization of GSK-3 inhibition 
in vivo by luciferase expression.  
 
1. BIOLOGICAL EFFECTS OF GSK-3 INHIBITORS 
1.1. Immunohistochemistry 
β-catenin is a one of the best studied substrates of GSK-3, and is involved in the 
regulation of cell junctions, and also in regulating gene transcription programs. However, 
its response to GSK-3 inhibitors has not been well studied in GBM or endothelial cells.  
Therefore, in this experiment we used immunostaining techniques to investigate the 
upregulation of β-catenin after employing three GSK-3 inhibitors (BIO, CHIR99021, and 
LiCl) in three cell lines (HBMEC, HUVEC, and U251 glioma cells) (Figures 6-8). 
Controls used were NaCl and DMSO. Cells were fixed and stained for β-catenin 24 hours 
after drug treatment. There was an up-regulation of total and nuclear β-catenin in cells 
treated with all three GSK-3 inhibitors. The endothelial cell samples had a greater total β-
catenin upregulation than the glioma cells. LiCl is previously known as an effective 
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GSK-3 inhibitor, and this experiment shows that BIO is even more potent while 
CHIR99021 has the greatest ability to induce β-catenin accumulation. 
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Figure 6. U251 Glioma Cell Immunohistochemistry. Figure shows more up-regulation 
of total and nuclear β-catenin as compared with endothelial cells (Figures 7 and 8). (A) 
DMSO, 0.1% (B) NaCl, 20mM (C) LiCl, 20mM (D) BIO, 2 µM (E) CHIR99021, 2µM. 	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Figure 7. HUVEC Immunohistochemistry. Figure shows less up-regulation of total and 
nuclear β-catenin as compared with glioma cells (A) DMSO, 0.1% (B) NaCl, 20mM (C) 
LiCl, 20mM (D) BIO, 2 µM (E) CHIR99021, 2µM. 	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Figure 8. HBMEC Immunohistochemistry. Figure shows less up-regulation of total 
and nuclear β-catenin as compared with glioma cells (A) DMSO, 0.1% (B) NaCl, 
20mM (C) LiCl, 20mM (D) BIO, 2 µM. 	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1.2. Adherens Junctions in Live Cells 
An adherens junction is a cell junction whose cytoplasmic face is linked to the 
actin cytoskeleton. Because we wanted to observe the changes in the cell-to-cell junction 
appearance in glioma cells after being treated with GSK-3 inhibitors, junctions were 
visualized using EGFP-β-catenin fusion protein in G9 glioma cells. This result was not 
observed in immunostaining of other cell lines. As shown in Figures 9 and 10, NaCl as a 
control showed fine, spikey cell-to-cell junctions in the cell membranes. LiCl led to an 
expected increase in the translocation of β-catenin to the nucleus as seen in other cells. 
Both CHIR99021 and BIO showed a total upregulation and nuclear translocation of β-
catenin, in addition to the cell-to-cell junctions becoming more smooth as compared to 
the spikey control NaCl. There was a heterogeneous response to both drugs between cells 
in the same dish, indicating that not all cells in the sample responded to the drugs in the 
same way. 
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Figure 9. Selected G9 Clones After 24-Hour Treatment With Drugs. Smoother 
junctions are seen with the BIO and CHIR99021 samples, while LiCl showed a 
translocation of β-catenin to the nucleus.  (A) NaCl, 20mM (B) LiCl, 20mM (C) 
BIO, 2µM (D) CHIR99021, 2µM. 	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Fig 10. Tight Junctions in Selected G9 Clones After 24-Hour Treatment With 
Drugs. Smoother junctions are seen with the BIO and CHIR99021 samples, while 
LiCl showed a translocation of β-catenin to the nucleus. (A) NaCl, 20mM (B) LiCl, 
20mM (C) BIO, 5µM (D) CHIR99021, 10µM.  	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1.3. Electric Cell-Substrate Impedance Sensing (ECIS) 
Another method which allows the assessment of cell-cell interaction is electrical 
cell-substrate impedance sensing (ECIS). In this technique the resistance to electrical 
flow created by a cell monolayer is measured using a slide with electrodes on the 
underside. Because we wanted to see the change in membrane permeability in HBMEC 
after treatment with GSK-3 inhibitors, we performed an experiment using ECIS, 
measuring cell layer resistance to current at 4,000 Hz. Both BIO and CHIR99021 were 
found to decrease the integrity of the cell monolayer and reduce resistance (Figure 11A). 
The top graph shows the data for monolayer of cells that was formed over 24h period, we 
expected that the cells did not have enough time to form mature tight junctions; therefore 
these results show adherens junction permeability and resistance. The bottom graph 
(Figure 11B) shows the data after a longer period of time (20 days) when the cells were 
able to form a mature monolayer (maturation of tight junctions was represented by stable 
and non-increasing resistance of the monolayer over period of at least 24 hours); 
therefore these show tight junction permeability and resistance. Both BIO and 
CHIR99021 show a significant decrease in resistance over time, while NaCl, LiCl, and 
DMSO each only have a slight reduction associated with changing condition of culture 
medium. 	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Figure 11. ECIS Graphs Measuring Normalized Resistance of HBMECs. 
(A) Cells did not form a mature monolayer, data show adherens junctions. (B) 
Mature monolayer was formed, data show tight junctions. (NaCl, 20mM; LiCl, 
20mM; 0.1% DMSO; CHIR99021, 10µM; BIO, 5µM.   	  
A 
B 
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1.4. Rat Aortic Ring Assay 
In this experiment, we wanted to see the effects of the GSK-3 inhibitors on the 
migration of endothelial cells from rat aortic rings (Figures 12 and 13). The controls 
NaCl and DMSO gave an expected result that showed the most migration as compared 
with the drugs used. LiCl showed the least amount of migration (approximately 2 million 𝑢𝑚!), while CHIR99021 and BIO showed slightly more (approximately 7 million 𝑢𝑚! 
and 4 million 𝑢𝑚!, respectively).  	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Figure 12. Rat Aortic Ring Assay. LiCl stopped all migration almost 
completely, while CHIR99021 and BIO slowed it. DMSO and NaCl showed no 
stoppage of migration. A) NaCl, 20mM. (B) LiCl, 20mM. (C) DMSO. (D) 
CHIR99021, 10µM. (E) BIO, 5µM.   	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1.5. HBMEC Sphere Assay 
Because we wanted to see the extent of the invasion of cells after treatment with 
GSK-3 inhibitors, we performed a sphere assay. In this experiment, HBMEC cells were 
cultured and treated with the drugs and their invasion was measured using area and 
perimeter of the sphere and invasive zone. As expected, NaCl and DMSO showed the 
most invasion of cells, while the drugs LiCl, BIO, and CHIR99021 showed reduction. 
Figure 13. Outgrowth Area in GSK-3 Inhibitor Treated Rat Endothelial Aortic 
Rings.    	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The perimeter of the NaCl and DMSO treated spheres were the most, also suggesting a 
high rate of invasion. CHIR99021 did not limit invasion as much as LiCl. The spheres 
treated with BIO showed a mild toxicity, making these results somewhat inconclusive.   
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Fig 14. Sphere Outgrowth in GSK-3 Inhibitor Treated HBMECs. BIO showed 
a toxicity, killing most all cells, while CHIR99021 showed a reduction in invasion. 
NaCl and DMSO showed no decrease in invasion. (A) NaCl, 20mM. (B) LiCl, 
20mM. (C) 0.1% DMSO. (D) CHIR99021, 10µM. (E) BIO, 5µM.   	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Figure 15. Quantitative Data for HBMEC Sphere Outgrowth. (Top) Auto-
Threshold Area of HBMEC Spheres After GSK-3 Inhibitor Treatment. 
(Middle) Perimeter of HBMEC Spheres After GSK-3 Inhibitor Treatment. 
(Bottom) Area of HBMEC Spheres After GSK-3 Inhibitor Treatment. 	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2. DEVELOPMENT OF A GSK-3 INHIBITOR REPORTER CELL LINE 	  
2.1. Cloning and TCF-LEF Luciferase Reporter Assay 
For cloning, we used a plasmid vector and a desired insert (see Methods 2: 
Cloning and TCF-LEF Luciferase Reporter Assay) to create a new construct containing 
luciferase, which was used as a reporter of β-catenin accumulation. We used the 
TCF/LEF reporter plasmid (pGL4.14/8xTCF-LEF-TA-β-catenin-binding) as a reporter of 
β-catenin transcriptional coactivation in response to GSK-3 inhibition. In order to 
determine the level of GSK-3 inhibition in drug-treated glioma cells, we assayed the 
activity of a β-catenin responsive luciferase reporter plasmid in GSK-3 inhibitor treated 
U251 cells. We were unable to transfect HUVEC and HBMEC cells with reporter 
plasmid in levels sufficient enough to observe β-catenin up-regulation. The luciferase 
signal was measured 6 hours after treatment with drugs. GSK-3 inhibition at 5µM BIO 
showed the highest level of luciferase signal. At concentration 10µM, the signal was less, 
suggesting BIO toxicity. CHIR99021 has the highest luciferase signal at 10µM, with a 
steady decrease at lower concentrations. The β-catenin transcriptional co-activation was 
observed al concentration as low as 0.66µM.  Background signals are shown in gray for 
error/comparison purposes.  
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Fig 16. Luciferase Signal of U251 Cells Transfected with pGL-TCF-
LEF-β-catenin After 20 Hours in Drugs. (Red: BIO; Blue: CHIR99021; 
Gray: Background). 
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DISCUSSION 
 
 As the most malignant form of primary adult brain tumors, glioblastoma 
treatments and cures are highly sought after. Patients with this cancer usually succumb to 
death within one year (Ray, 2010). GBM is a devastating diagnosis. GBM cells have a 
high rate of invasion and angiogenesis into nearby normal brain tissue, making 
completely surgical resection almost impossible, and creating a devastating prognosis for 
those afflicted with GBM. Conventional treatments like radiotherapy and cytotoxic 
chemotherapy definitely have an effect on prognosis, but are not an adequate cure as they 
are unable to overcome the malignant biology of the tumor cells and usually result in a 
recurrence. It is obvious that new treatment modalities must be developed to have a more 
targeted and adequate mechanism of action and to have the ability to give a much better 
prognosis for patients. New treatments also need to focus on the invasion and migration 
of GBM tumor cells. 
GSK-3 is a multifunctional serine-threonine protein kinase that regulates many 
processes, including metabolism, cell fate specification, cell division, and cell death. 
Examples of pathways where GSK-3 is involved are Wnt, notch, tyrosine kinase, G-
protein couple receptor signaling, and PI3K/Akt/mTOR. Because of these roles and its 
role in the regulation of cell motility, GSK-3 has become a very important target for 
multitudes of treatments for cancers, Alzheimer’s disease, diabetes, and bipolar disorder 
(Williams et al., 2011). There have also been concerns about possible consequences of 
inhibiting GSK-3, as the inhibition upregulates the phosphorylation of β-catenin, which 
has been shown to have oncogenic effects in some cell types, however, patients who have 
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been treated with GSK-3 inhibitors have not been shown to have an increase in tumor 
number. Past investigations have concluded that tumor growth can be controlled with the 
use of GSK-3 inhibitors: an increase in cell death and a decrease in tumorigenicity 
(Kotliarova et al., 2008). 
 Previous work has shown that lithium, at high concentrations, will block glioma 
cell migration in part through GSK-3 inhibition. Unfortunately the concentration for 
lithium must be 20mM to have a significant effect, and this concentration is quite harmful 
to humans, who have a tolerance of 2mM. Based on previous observations, at lower 
concentrations lithium may not create enough of a blockade of glioma cell migration. 
Therefore more studies need to be done to identify suitable and more effective candidates 
for anti-invasive therapies of GBM.  
Here we studied anti-invasive therapies that may have a future role in GBM 
treatment. It is thought that combining conventional treatments with anti-invasive 
therapies will create cytotoxicity in and reduce migration of the tumor. We reported that 
GSK-3 inhibitors might have a valuable role in the treatment of GBM. The selected 
inhibitors (BIO, CHIR99021, and LiCl) all were shown to lessen cell migration and 
invasion in vitro in a range of assays and in all cell lines tested. All inhibitors tested cause 
a dose-dependent, reversible inhibition of glioma cell invasion in spheroid assays. BIO 
was shown to cause a rapid upregulation of total and nuclear β-catenin. BIO, at higher 
concentrations, also created a toxic environment for cells, sometimes killing them. This 
shows that a more in-depth experiment involving different BIO concentrations is needed 
to test the optimal concentration for treatment.  
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Each of the experimented GSK-3 inhibitors also showed a change in the junctions 
between cells. NaCl as a control showed normal, spikey, junctions, while CHIR99021 
and BIO caused the junctions to become more smooth. This suggests that GSK-3 
inhibition has a role in either maintaining the ECM and/or in communication between 
cells. Also in this assay, there was a heterogeneity between cells treated with the same 
inhibitor and in the same dish, indicating that not all cells respond to each drug the same 
way. The reasons for this are not known and further investigation is required.  
As is previously known, a tight monolayer gives greater electrical resistance. The 
ECIS technique is often used as an in vitro method to assess barrier functions in 
endothelial cells. Tight junctions require a longer period of time to form within a 
monolayer, while adherens junctions take a shorter period. BIO and CHIR99021 show a 
reduction in resistance and a decrease in the integrity of the cell monolayer over time, 
suggesting a role of GSK-3 inhibitors in the increase in permeability of endothelial cells. 
This is a possible avenue to increase the effectiveness of the drug in reaching the tumor.  
The degree of GSK-3 inhibition, which we measured by a luciferase reporter 
assay of β-catenin transcriptional activation, showed an inverse correlation with the 
degree of invasion, suggesting a direct link between GSK-3 activity and the rate of 
glioma invasion. β-catenin is a key mediator of glioma migration. In the β-catenin 
luciferase assay both BIO and CHIR99021 led to a greater activation of β-catenin than 
LiCl.   
 The further development and research of GSK-3 inhibitors is a promising path for 
the future of the treatment of GBM and the future of medicine.  
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